RE-ALIGN: Dabigatran use not supported in patients with mechanical heart valves

  • September 1, 2013

AMSTERDAM — Use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic events and bleeding complications in the RE-ALIGN study.

The phase 2, dose-validation study focused on two patient populations: those who had undergone aortic or mitral valve replacement within the week before the study and those who had undergone replacement at least 3 months before the study.

More »

Additional headlines from ESC Congress 2013

See All »

Recent Meetings